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Abstract
Background: PTEN is a tumor suppressor gene which is involved in cellular proliferation, differentiation, and apoptosis.
Loss or down-regulation of PTEN plays an important role in human cancers development. In this study, we investigated
the effect of miR-21 and promoter methylation on the PTEN expression status in CRC tissues and analyzed association
of the PTEN expression status with clinicopathological features in patients with CRC.
Results: The PTEN expression was positively detected in 67.2 % CRC tissues and all adjacent non-cancerous samples.
PTEN mRNA level was negatively correlated with miR-21 level (r = −0.595, P < 0.001). PTEN expression was also correlated
directly with the PTEN mRNA level (r = 0.583, P < 0.001) and conversely with miR-21 level (r = −0.632, P < 0.001). PTEN
Promoter methylation was significantly associated with PTEN expression status (p = 0.013). PTEN expression was
negatively associated with tumor size (p = 0.007) and advanced tumor stage (P = 0.011). Multivariate analysis indicated
that tumor stage, tumor differentiation and PTEN expression status were independent prognostic factors for overall
carcinoma in CRC patients (P < 0.05). The Kaplan-Meier curve indicated a negative correlation between PTEN expression
levels and survival of CRC patients (P = 0.013).
Conclusions: This study suggests a high frequency of miR-21 overexpression and aberrant promoter methylation in
down-regulation of PTEN expression in colorectal carcinoma. Loss of PTEN may be a prognostic factor for patients with
CRC.
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Background
Colorectal cancer (CRC) is the third commonly diagnosed
cancer worldwide, with approximately 1.3 million new
cases and half million deaths annually [1]. The develop-
ment of CRC from normal endothelium to advanced car-
cinomas involves a multiple process with accumulation of
genetics and epigenetics changes, leading to a high activity
of oncogenes and low activity or dysfunction of tumor
suppressor genes [2]. To date, despite great effort to
clarifying the molecular mechanisms in CRC, the molecu-
lar pathogenesis of CRC remains unclear.
PTEN (phosphatase and tensin homolog deletion on
chromosome 10) is a tumor suppressor protein with the
phosphatase activity and acts as a negative regulator in
the PI3K/AKT pathways. This pathway control several
processes related to cell metabolism, proliferation and
survival. PTEN plays an essential role in the silencing of
signal transduction from several membrane growth fac-
tor receptors (Her1, Her2 and IGFR) through the PI3K/
AKT signaling cascade [3, 4]. Apart from phosphatase
activity, PTEN forms a nuclear complex with p53 pro-
tein, a tumor suppressor protein. This complex inhibits
p53 decomposition and increases its transcriptional ac-
tivity [5, 6]. Nuclear PTEN induce arrest in the G0-G1
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phase of cell cycle by down-regulation of cyclin D1 and
ERK/MAPK pathway [7]. In many tumor types, genetic
alterations of PTEN gene enhance tumorigenesis and
may determine aggressive clinicopathological behavior of
a tumor [8–11]. The role of PTEN in CRC was postu-
lated earlier as one of the factors of PTEN hamartoma
tumor syndrome that the estimated lifetime risk of CRC
in these patients is 9 % [9, 11]. Previous studies indicate
that PTEN gene mutations in sporadic CRC are rare
[12–14] and other mechanisms might be involved in in-
activation of PTEN, such as promoter hypermethylation
and microRNAs [15, 16].
MicroRNAs are a class of short non-coding RNAs with
18–25 nucleotides in length. Those negatively regulate
gene expression by complementary binding to the 3′-un-
translated region of target mRNAs; this causes translation
inhibition or mRNA degradation [17]. Many Studies have
demonstrated the important role of microRNAs in almost
all cellular processes including proliferation, metabolism,
differentiation, apoptosis and the immune response
[18–20]. MicroRNAs have been demonstrated to play a
significant role in the multi-step process of carcinogenesis
[21, 22]. Recent reports show that miR-21 is consistently
overexpressed in many types of tumors. PTEN mRNA has
been known as one of miR-21 targets that significantly as-
sociated with several malignancies in human [23–25].
However, the expression levels of miR-21 and PTEN
mRNA have not been sufficiently studied in CRC.
DNA methylation is an important mechanism in epi-
genetic control, which has been involve in the develop-
ment of many of cancers [26]. Hyper-methylation of some
tumor suppressor genes has been related to the initiation
and development of various human cancers [27, 28].
Hypermethylation of PTEN gene contributes to CRC de-
velopment is not yet clarify and needs more studies.
In this study, we assayed impact of miR-21 and pro-
moter methylation on the PTEN expression status in CRC
tissues and analyzed correlation of the PTEN expression
with clinicopathological features in CRC patients.
Methods
Subjects
One hundred and twenty-five samples of Formalin-fixed
paraffin-embedded (FFPE) colorectal carcinomas and ad-
jacent non-cancerous tissues were collected from the
sporadic CRC patients who had surgery between March
2005 and October 2011. None of the patients were treated
by chemotherapy or radiotherapy before surgery. Clinico-
pathological features of patients were obtained from med-
ical records. The survival time was considerate from the
diagnosis date to the last follow-up date. This study was
approved by the Clinical Research Ethics Committee in
Golestan University of Medical Science.
Immunohistochemistry (IHC)
PTEN IHC was performed on 5 μm unstained micro-
dissected tissue blocks using a mouse monoclonal anti-
body (6H2.1, Dako, California, USA) (1:100 dilutions).
After deparaffinization, antigen was retrieved on sections
(100 °C, pH = 9.0, 25 min). The sections were then sub-
merged in anti-PTEN antibody (35 °C, 15 min). Subse-
quently, they were submerged in hydrogen peroxide (35 °
C, 5 min) for deactivation of the endogenous peroxidase.
Following these steps, the sections were covered with sec-
ondary anti-mouse immunoglobulin (35 °C, 8 min). Di-
aminobenzidine was applied as a chromogen and sections
were counterstained using hematoxylin. The stained slides
were examined using light microscopy (Olympus BX41,
Richmond Hill, Canada). The percentage of PTEN immu-
nostaining tumor cells was identified and a semiquantita-
tive scoring system was applied to evaluate the staining
results (0, < 5; 1+, 5–25; 2+, 25–50; and 3+, > 50 %).
Primer design
The amplification primers for specific-recognizing of
PTEN complementary DNA (cDNA) and Hypoxanthine-
guanine phosphoribosyltransferase (HPRT) cDNA were
designed by Gene Runner software (version 3.05; Hastings,
USA). Methylation-Specific PCR (MSP) primers of PTEN
promoter were designed as described by Zysman et al.
[29]. All primers were reviewed in NCBI and BLAST web-
sites (Table 1).
Quantitative reverse transcriptase Polymerase Chain
Reaction (QRT-PCR)
Total RNA was extracted from micro-dissected FFPE
weighing 50 mg by PureLink FFPE RNA Isolation Kit
(Invitrogen, Carlsbad, USA) and modified to first strand
cDNA using miScript II RT Kit (Qiagen, Hilden, Germany)
according to the manufacturer’s protocol. For analysis of
PTEN mRNA levels, QRT-PCR was performed using
primers set and by Maxima SYBR Green/ROX qPCR Mas-
ter Mix (Fermentas, Sankt Leon-Rot, Germany). MiR-21
was also quantified using the forward primer and miScript
SYBR Green PCR Kit (Qiagen, Hilden, Germany) accord-
ing to the manufacturer’s protocol. Each sample was tested
in triplicate, in 7500 Real-Time PCR system (Applied Bio-
system, Foster City, USA) and was normalized to endogen-
ous control. The expression level was calculated using
average of the 2-ΔCt (ΔCt = Ct of control gene - Ct of target
gene) [30].
Promoter methylation assay
Genomic DNA (1 μg) of micro-dissected tumor tissues
was extracted by the MagMA FFPE DNA Isolation Kit
(Invitrogen, Carlsbad, USA) according to the manufac-
turer’s protocol. Bisulfite modification was performed by
EpiTect Fast Bisulfite Conversion Kit (Qiagen, Hilden,
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Germany) according to the manufacturer’s protocol. MSP
was performed using 100 ng of bisulfite-modified DNA,
primers set and Taq DNA Polymerase Master Mix
(Ampliqon, Copenhagen, Denmark) in a final volume of
25 μl in thermal cycler instrument (Eppendorf, Hamburg,
Germany). MSP were analytically validated using standard
methylated DNA as positive control (Chemicon, Temecula,
USA) and primary keratinocyte DNA as negative controls.
The amplification products were electrophoresed on a
2.5 % agarose gel, stained in sybr green, and visualized by
UV transilluminator (Uvitec, Cambridge, UK). The MSP
results were reported as methylated samples (a band
173 bp) and unmethylated samples (a band 155 bp). MSP
results of PTEN promoter were also confirmed by bisulfite
sequencing.
Statistical analysis
The correlation of PTEN expression status to PTEN
mRNA level and miR-21 levels was tested by Spearman
correlation analysis. The association between PTEN ex-
pression status and Clinicopathological features were
analyzed by ANOVA and Fisher’s exact tests. The sur-
vival curves were estimated by the Kaplan-Meier method
and the log rank test was applied to compare the differ-
ences between curves. Multivariate analysis was per-
formed by the Cox regression model. Data were analyzed
using SPSS software version 17.0 (SPSS Inc. Chicago,
USA). A p-value of less than 0.05 was considered statisti-
cally significant.
Results
PTEN expression and factors affecting it in CRC
Positive PTEN staining was detected in the nucleus of
corresponding normal mucosa (Fig. 1a) or carcinoma
cells (Fig. 1b). In some cancerous samples, no PTEN ex-
pression was observed (Fig. 1c). PTEN expression was
positively (1+, 2+ and 3+) detected in 67.2 (84 of 125)
of CRC tissues and 100 % of adjacent non-cancerous
samples. PTEN expression in CRC tissues was statisti-
cally lower than the non-cancerous mucosa (P < 0.001)
(Table 2).
Fig. 1 Representative IHC staining of colorectal samples. a PTEN was positively expressed in adjacent normal tissue (b) and colorectal carcinomas.
c Negative expression for PTEN was observed in some CRC tissues samples (x200)
Table 1 The used primers in this study
Amplified factor primers 5′ to 3′ Product size (bp) AT (°C) Genbank accession number
miR-21 S TGTCGGGTAGCTTATCAGAC ~90 55 NR_029493
AS Adapter primer in kit
U6-snRNA S GCTTCGGCAGCACATATAC ~120 55 NR_004394
AS Adapter primer in kit
PTEN S ACCAGAGACAAAAAGGGAGTA 173 56 NM_000314
AS ACCACAAACTGAGGATTGCA
HPRT S TGGACTAATTATGGACAGGACT 219 56 NM_000194
AS CCTGTTGACTGGTCATTACAAT
PTEN Promoter
Unmethylated (−300)a S-U TGGGTTTTGGAGGTTGTTGGT 173 55 NG_007466.2
AS-U ACTTAACTCTAAACCACAACCA
Methylated (−298)a S-M GGTTTCGGAGGTCGTCGGC 155 57
AS-M CAACCGAATAATAACTACTACGACG
S sense, AS antisense, U unmethylated, M methylated, AT annealing temperature
aDistance of the 5′ nucleotide of the sense primer from the transcription start site of PTEN gene
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The results indicated that the average of miR-21 level
(Mean ± SD, 2.113 ± 0.652) in cancerous tissues was sig-
nificantly high compared with normal tissues (1.211 ±
0.512) (p = 0.014) (Fig. 2a). In contrast, the level of PTEN
mRNA was significantly down-regulated in tumor tissues
(1.278 ± 0.712) compared with normal tissues (2.291 ±
0.935) (p = 0.009) (Fig. 2b). The correlation coefficient test
indicated that PTEN mRNA level was negatively corre-
lated with miR-21 level (r = −0.595, P < 0.001) (Fig. 3a).
PTEN expression was also correlated directly with the
PTEN mRNA level (r = 0.583, P < 0.001) (Fig. 3b) and con-
versely with miR-21 level (r = −0.632, P < 0.001) (Fig. 3c).
MSP analysis of CRC tissues using PTEN promoter spe-
cific primers showed that 39 samples (31.2 %) have been
methylated (Fig. 4a). As Table 3 shows, 85 % (33 of 39) of
the methylated CRC samples showed loss or reduced
PTEN protein staining (0 and 1+). Comparison of methyl-
ated and unmethylated groups based on the IHC scores,
shows that the frequency of PTEN Promoter methylation
has decreased in groups with the increased IHC staining
score. (p = 0.013). We studied normal tissues for investiga-
tion of the possibility of PTEN promoter methylation, and
none of those showed aberrant methylation (Fig. 4a). The
MSP data were confirmed by bisulfite sequencing on some
of the methylated sporadic CRC samples. These data
clearly showed that specific sequence belonged to the
PTEN gene promoter and not the pseudogene (Fig. 4b).
Moreover, level of PTEN mRNA was significantly high in
unmethylated samples (2.452 ± 1.536) compared with
methylated samples (1.213 ± 0.671) (p = 0.011) (Fig. 4c).
PTEN expression status and clinicopathological features
Comparison of clinicopathological groups based on the
IHC scores have been shown in Table 3, positive PTEN ex-
pression was associated negatively with tumor size (p =
0.007) and positively with advanced tumor stage (P =
0.011), but no association was observed with age, gender
and tumor differentiation (P > 0.05) in CRC patients.
Multivariate analysis using Cox’s proportional method in-
dicated that tumor size, tumor stage and PTEN expression
status were independent prognostic factors in overall CRC
(P < 0.05) (Table 4). Follow-up information was available
on 101 CRC patients for 40 ± 22 (3 to 80) months. Kaplan-
Meier curve indicated a negative correlation between
PTEN expression levels and survival of CRC patients. It
shows that the overall survival has increased in accordance
with the increased IHC score. (P = 0.013) (Fig. 5).
Discussion
PTEN is a tumor-suppressing gene which is involved in
cellular metabolism, proliferation, differentiation, and
apoptosis. Loss or down-regulation of PTEN plays an
important role in development and progression of ma-
lignancies [3–6]. The different mechanisms may be in-
volved in the regulation of PTEN expression including
mutations, promoter methylation, microRNAs, posttrans-
lational regulation, and the PTEN protein stability [3, 10,
24]. Among these factors, Down-regulation of PTEN gene
by promoter methylation and microRNA targeting has
been reported in many types of human cancers [21–24, 27,
28]. Recent studies about PTEN gene dosage on both
humans and mice indicated that even partial loss of func-
tion is sufficient for development of some cancer types
[31], suggests that the evaluation of minor changes in
PTEN expression is crucially important. In the present
Table 2 PTEN expressions in CRC tissues and matched
non-cancerous tissues
Tissue type N. PTEN expression P-value
0 1+ 2+ 3+ PR (%)
Non-cancerous 125 0 18 59 48 100 <0.001
Cancerous 125 41 34 37 13 67.2
PR positive rate
Fig. 2 QRT-PCR analysis of miR-21 and PTEN mRNA in CRC patients. a The level of miR-21 in tumor tissues was significantly higher than non-tumor
tissues. b Level of PTEN mRNA in tumor tissues was significantly lower than non-tumor tissues. Horizontal lines indicate the mean values. Differences
between groups were analyzed using the Student’s t-test
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study, we measured the expression of PTEN mRNA and
protein in CRC tissues and analyzed the effect of miR-21
level and aberrant promoter methylation on reduction or
loss of PTEN expression. In this study, IHC results shows
67.2 of CRC samples were PTEN-positive and 32.8 % were
negative (Table 2), that is closed to previous studies results
[32, 33]. MiR-21 is one of the most important microRNAs
in human cancer and is known as a potential oncogene.
MiR-21 is up-regulated in various carcinoma types and has
been correlated with poor therapeutic outcome and poor
survival [34–36]. In the present study, the level of miR-21
was significantly higher in cancerous tissues than normal
tissues (Fig. 2a). Correlation analysis of IHC results also
shown, MiR-21 level was negatively correlated with PTEN
expression (Fig. 3). In addition, miR-21 was over-expressed
in 75.5 % cancerous tissues with reduced or lost PTEN
protein. These findings confirmed role of miR-21 in regula-
tion of PTEN expression in CRC. These results are consist-
ent with other studies [34–39] suggesting that the high
expression of miR-21 might be an early diagnosis marker
in CRC. Epigenetic silencing of PTEN gene by promoter
methylation was initially proposed in prostate cancer cell
Fig. 3 Scatter plots for three correlation outcomes in CRC tissue samples. a Scatter plot for correlation analysis between PTEN mRNA level and
miR-21 level, b PTEN mRNA level and IHC scores, c and miR-21 level and IHC scores
Fig. 4 Representative results of MSP analysis of the PTEN gene in CRC patients. a The Methylation status was determined based on Product
size-band; 176 bp for unmethylated and 155 bp for methylated. Universal methylated and unmethylated DNA was used as a positive control.
Water was used as a negative control. N, normal tissue; T, tumor tissues; M, methylated; U, unmethylated. b Bisulfite sequencing of the PTEN
promoter was performed using primers of methylation analysis on the methylated samples. Bisulfite sequencing results indicated that the
sequence shown in the electropherograms matched the PTEN gene at the one critical nucleotide positions (marked with arrows and box).
c The level of PTEN mRNA in methylated samples was significantly lower than unmethylated samples. Horizontal lines indicate the mean
values. Differences between groups were analyzed using the Student’s t-test. d Part of the PTEN promoter region. +1 indicates the translation start site
and the location of the primer set is marked using number. Differences between unmethylated and methylated sequences on primers are shown in
bold. The CpG sites are in box and common methylated sites in all methylated samples are marked by asterisk
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lines and identified as an effective mechanism in melan-
oma development [40]. The genomic sequence of PTEN
promoter is very identical to 841 bp in a highly conserved
region on PTEN pseudogene. As a consequence, the ex-
treme caution needs to select primer set when analyzing
the PTEN promoter methylation [29]. Following these
recommendation, in this study, we reported a 31.2 % fre-
quency for PTEN promoter methylation in CRC tissues.
Moreover, we found that 85 % of the methylated CRC
samples showed reduced or lost PTEN protein (Table 3),
suggests high frequency of PTEN aberrant promoter
methylation in colorectal carcinoma. These findings along
with other results [15], suggest that the PTEN promoter
methylation might be cancer specific and plays a role in
the development of these neoplasms. Low expression
PTEN mRNA in tumor and methylated samples com-
pared with non-tumor and unmethylated samples (Fig. 2)
demonstrated that PTEN expression status is a critical
modulator in CRC development. We found that negative
PTEN expression was statically associated with tumor size
and advanced TNM stages in patients with colorectal car-
cinoma (Table 3), similar to a Waniczek et al. and Chow
et al. studies [4, 41] but in contrast with Goel et al. study
[15]. Multivariate analysis also showed for the first time
that tumor size is an independent prognostic factor for
overall carcinoma in CRC patients with low or lost PTEN
expression (Table 4). In agreement with Jang et al. study
[42], Survival analysis of present study indicated that the
patients with loss of PTEN expression showed poorer sur-
vival than the patients with normal expression. These re-
sults were suggested that down-regulated expression of the
PTEN protein probably contributed to growth, invasion,
and metastasis of colorectal carcinoma and could be con-
sidered as a good marker to indicate the aggressive behav-
iors and poor prognosis of colorectal carcinomas. The
results of this study and other similar studies indicated that
the PTEN loss is a key factor in tumor development and
its expression regulation may be a good target for develop-
ing drugs to prevent cancer progression in the feature.
Conclusions
This study suggests a high frequency of miR-21 overex-
pression and aberrant promoter methylation in down-
regulation of PTEN expression in colorectal carcinoma.
Loss of PTEN may be a prognostic factor for patients with
CRC. Analysis of PTEN expression profile may be a useful
test for prognosis of CRC and reduces the cost of unneces-
sary use of antiviral drugs against growth factor receptors.
Table 3 Relationship between PTEN expression and
clinicopathological data in CRC patients
Clinicopathological features N. PTEN protein expression P-value
0 1+ 2+ 3+ PR (%)
Total cases (cancerous) 125 41 34 37 13 67.2
Age 0.943
< 50 18 6 4 6 2 66.7
≥ 50 107 35 30 31 11 67.2
Sex 0.251
Female 55 15 16 18 6 72.7
Male 70 26 18 19 7 62.8
Tumor size (cm) 0.007
≤ 5 79 19 23 27 10 76
> 5 46 22 11 10 3 52.2
TNM Stage 0.011
I & II 25 3 6 12 4 88
III & IV 100 38 28 25 9 62
Tumor Differentiation 0.534
High 65 19 17 18 11 70.8
Moderate 49 17 14 16 2 65.3
Low 11 5 3 3 0 54.5
PTEN Promoter methylation 0.013
Methylated 39 18 15 4 2 53.8
Unmethylated 86 23 19 33 11 73.2
PR positive rate, TNM Tumor, Node Metastases staging system
Table 4 The multivariate analysis of clinicopathological variables
for overall survival in CRC patients
Clinicopathological variables Relative risk (95 % CI) P-value
Age (≥50) 0.980 (0.70 - 1.12) 0.352
Sex 1.26 (0.81 - 1.78) 0.237
Tumor size (>5 cm) 2.11 (1.01 - 3.97) 0.010
Stage ( III & IV) 1.59 (0.73 - 2.89) 0.013
Differentiation (low) 1.51 (1.03 - 2.44) 0.094
PTEN expression 2.23 (1.06 - 4.68) 0.008
CI Confidence Interval
Fig. 5 Kaplan-Meier curves for overall survival in patients with CRC. The
overall survival has increased in accordance with the increased IHC score
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